As shown in Figure 8A–D, changes in the intratumoural expression levels of these enzymes, resulting in an increase in the E1:E2 ratio, are associated with a worse patient outcome for ER+ ovarian cancer disease. This evidence concerns the gene ESR1 and ovarian cancer.